Assessment of MYCN amplification status in Tunisian neuroblastoma: CISH and MLPA combining approach

Dorra H'Mida, Ben Brahim; Saoussen, Trabelsi; Imen, Chabchoub; Inesse, Gargouri; Imed, Harrabi; Adnene, Moussa; Maroua, Chourabi; Marwa, Haddaji; Sihem, Sassi; Soumaya, Mougou; Moez, Gribaa; Slim, Ben Ahmed; Abdelfattah, Zakhama; Abdellatif, Nouri; Ali, Saad

Dorra H'Mida, Ben Brahim; Saoussen, Trabelsi; Imen, Chabchoub; Inesse, Gargouri; Imed, Harrabi; Adnene, Moussa; Maroua, Chourabi; Marwa, Haddaji; Sihem, Sassi; Soumaya, Mougou; Moez, Gribaa; Slim, Ben Ahmed; Abdelfattah, Zakhama; Abdellatif, Nouri; Ali, Saad.

Tunisie Medicale [La]. 2015; 93 (8/9): 527-531

em Inglês | IMEMR | ID: emr-177397

ABSTRACT

ABSTRACT

Background:

Neuroblastoma [NB] shows a complex combination of genetic aberrations. Some of them represent poor genetic prognosis factors that require specific and intensive chemotherapy. MYCN amplification consists of the major bad outcome prognostic factor, it is indeed frequently observed in aggressive neuroblastomas. To date different methods are used for MYCN status detection

Buscar no Google

Imprimir

XML

Índice: IMEMR (Mediterrâneo Oriental) Idioma: Inglês Revista: Tunisie Med. Ano de publicação: 2015

Similares

MEDLINE

LILACS

LIS

Buscar no Google

Imprimir

XML

Índice: IMEMR (Mediterrâneo Oriental) Idioma: Inglês Revista: Tunisie Med. Ano de publicação: 2015